October 3rd, 2022
The global Pruritus Therapeutics Market was estimated at USD 12.11 billion in 2021 and is projected to reach USD 16.37 billion by 2028, growing at a CAGR of 4.4% over the analysis period.
Pruritus is also known as itching, which is an annoying and uncontrollable sensation that causes one to scratch, in order to relieve the discomfort. Dry skin, skin diseases, and pregnancy are some of the possible causes of itchiness. Rashes, bumps or any visible signs of irritation may appear on the skin during pruritus. Some diseases or conditions that cause pruritus include contact dermatitis, scabies, food or substance allergies, allergic eczema, psoriasis, urticaria, systemic lupus erythematous (SLE), and chicken pox. Some allergic reactions may lead to anaphylaxis, a severe form of allergic reaction which can also be life threatening
Read More: https://introspectivemarketresearch.com/reports/pruritus-therapeutics-market/
Pruritus is a sensation that causes the desire or reflex to scratch. Pruritus has resisted many attempts to classify it as any one type of sensory experience. Modern science has shown that Pruritus has many similarities to pain, and while both are unpleasant sensory experiences, their behavioral response patterns are different. Pain creates a withdrawal reflex, whereas Pruritus leads to a scratch reflex.
Major Key Players for Pruritus Therapeutics Market:
· AbbVie Inc.
· Sanofi SA
· Galderma Laboratories LP
· EPI Health LLC
· Cara Therapeutics
· Trevi Therapeutics
· Novartis AG
· Pfizer Inc.
· Merck & Co. Inc.
· Sun Pharmaceuticalc
· Glenmark Pharmaceuticals Ltd.
· Abbott Laboratories, and Other Major Players.
Download a Free Sample Copy of the Market Report:
Market Dynamics and Factors:
The increasing product launches and approvals is expected to boost global pruritus therapeutics market growth. For instance, on May 26, 2020, Sanofi, a global biopharmaceutical company dedicated to human health, announced that the U.S. Food and Drug Administration (FDA) has approved its Dupixent (dupilumab) for children between 6 to 11 years with moderate-to-severe atopic dermatitis (eczema) with pruritus as one of its major symptom. This disease in children is not adequately controlled by topical prescription therapies or those therapies that are contraindicated. Dupixent is the only biologic medicine approved for this patient population in treating eczema with pruritus.
Inquiry Before Purchase:
Pruritus Therapeutics Market Segmentation:
By Drug Class
· Calcineurin Inhibitors
By Disease Type
· Allergic Contact Dermatitis
· Atopic Dermatitis
Regional Outlook (Revenue in USD Million; Volume in Units, 2022-2028)
· North America (U.S., Canada, Mexico)
· Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
· Asia-Pacific (China, India, Japan, Southeast Asia, Rest of APAC)
· Middle East & Africa (GCC Countries, South Africa, Rest of MEA)
· South America (Brazil, Argentina, Rest of South America)
Purchase This Report:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assisting our clients to grow and have a successful impact on the market. Our team at IMR is ready to assist our clients to flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, that specializes in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyze extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.
Introspective Market Research
3001 S King Drive,
Ph no: +1-773-382-1047
Linkedin| Twitter| Facebook
Email : email@example.com
Add Sid0144 to your subscriptions feedSid0144
To notify a previous commenter, mention their user name:
@peter-smith if there are spaces.